Blood drawings

PROCEDURE2 trials

Sponsors

Apogenix GmbH, Heidelberg ImmunoTherapeutics GmbH

Conditions

Herpes LabialisMyelodysplastic Syndrome

Phase 1

APG101 in Myelodysplastic Syndrome

CompletedNCT01736436

Apogenix GmbHMyelodysplastic Syndrome

Start: 2013-01-31End: 2015-12-31Updated: 2016-08-24

Phase 2

Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection

TerminatedNCT04539483

Heidelberg ImmunoTherapeutics GmbHHerpes Labialis

Start: 2020-10-08End: 2023-05-31Updated: 2023-09-25

Related Papers

Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms

Annals of Hematology2024-02-272 citations

Safety and efficacy of the CD95-ligand inhibitor APG101 in transfusion-dependent patients with low risk MDS: Interim results from a phase I study.

Journal of Clinical Oncology2016-05-20